Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
CONNECT WITH US
Get in touch
Welcome to call or send an email!
Petra Larson, Communications lead
+46 (0)709 13 10 08
petra.larson@pharmnovo.com
Find us: PharmNovo AB, Medicon Village AB, Scheeletorget 1, SE-223 81 Lund, Sweden
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read morePharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read moreWe are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more
